The AJMC® Comprehensive Genomic Profiling compendium is a comprehensive resource for clinical news and expert insights for the next-generation sequencing approach to assess genes for the purpose of therapy guidance.
Lack of CGP Testing May Result in Missed Therapy Options in NSCLCJune 28th 2022
A real-world analysis found that comprehensive genomic profiling (CGP) in patients with non–small cell lung cancer (NSCLC) increases their therapy options patients and CGP testing needs to be utilized more.
AACR Posters Demonstrate CGP for Biomarker Detection and Multiomics ProfilingJune 11th 2022
Posters from the American Association of Cancer Research (AACR) Annual Meeting demonstrated the use of genomic profiling and sequencing can detect immunotherapy biomarkers and predict clinical outcomes in patients with cancer.
Contributor: The Case for Education and Clinical Decision Support With PharmacogeneticsJune 2nd 2022
Prescribing is a complex process with multiple factors to consider on top of the 3 primary questions about effectiveness, harm, and cost. Pharmacogenetics has put this complexity under the spotlight and prompted educational programs and the development of new clinical decision support systems.
Contributor: The Convergence of Value-Based Care and Lab Testing GrowthMay 17th 2022
Today, health plans are shifting dollars to more value-based contracts along with investments in population health management. Digitizing lab results across all care settings and unlocking the potential of lab values can help health plans reach the Triple Aim of improving the patient experience, improving the health of populations, and reducing the per-member cost of health care.
Contributor: Top 3 Future Therapies to Drive Hemophilia Treatment Market GrowthApril 24th 2022
The trends in the hemophilia treatment market are gaining momentum with increasing incidences of hemophilia A and B and staggering need for their treatments, including gene, anti-tissue factor pathway inhibitor, and factor replacement therapies.
NPC's Michael Ciarametaro on How Clinics Can Surmount Gene Therapy Data Collection BarriersApril 22nd 2022
Michael Ciarametaro, MBA, vice president of research at the National Pharmaceutical Council, highlights steps clinics can take to mitigate issues related to data collection regarding cell and gene therapies.
Spotlighting Health-, Cost-Related Benefits of Genomic Testing and How Employers Can Drive AdoptionApril 20th 2022
Key opinion leaders addressed cost, accessibility, and other barriers limiting use of comprehensive genomic profiling (CGP), and how employers can help drive preventive care and precision medicine through CGP.
Expert: Better Harmony Is Needed to Prevent Compromised Specimens During CGP TestingApril 15th 2022
Despite technological advancements, there are still many factors that can cause specimens for comprehensive genomic profiling (CGP) testing to become compromised, potentially leading to inaccurate prognostic results, according to a recent webinar.
Genomic Profiling Utility for Targeted Therapy Selection Shown in Advanced GI CancersApril 8th 2022
The clinical utility of genomic profiling was demonstrated in patients with advanced gastrointestinal (GI) cancers whose access to targeted therapies based on tissue-based assay findings was similar to those with non-GI cancers.
Dr Jorge Plutzky: New Advances in Science, Medicine Need to Move Into Practice QuickerApril 6th 2022
The acceleration of science and medicine is exciting, but these new advances are not always moving into practice, said Jorge Plutzky, MD, director of the Vascular Disease Prevention Program and director of Preventive Cardiology at Brigham and Women’s Hospital, and associate professor of medicine at Harvard Medical School.
Dr Edmondo Robinson Highlights the Importance of a Complete Patient View When Delivering CareMarch 30th 2022
Everything from the genomic data for the cancer to the zip code of a patient matters when delivery care, said Edmondo Robinson, MD, MBA, MS, FACP, senior vice president and chief digital officer at Moffitt Cancer Center.
ASCO GU 2022: Comparing Tumor Genomic Landscape Across Age, Disease DemographicsMarch 28th 2022
Posters from the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) 2022 look at how the tumor genomic landscape differs based on age and type of urothelial carcinoma.
What We're Reading: ACA Enrollment Expands; Seizure Disorder Treatment Approved; Biomarker Testing Program LaunchMarch 22nd 2022
The special enrollment period for Affordable Care Act (ACA) coverage has opened to low-income Americans; the FDA approves the first drug for a rare genetic epilepsy disorder; the National Institutes of Health to launch biomarker testing program for pediatric tumors.
FDA Approves FoundationOne CDx to Identify EGFR Therapeutics for Certain Patients With NSCLCMarch 19th 2022
FoundationOne CDx has been approved as a companion diagnostic to identify patients with non–small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 alternations eligible for treatment with EGFR tyrosine kinase inhibitors.
Mount Sinai Researchers Discuss Milestones in Understanding Genetic VariantsMarch 14th 2022
Ron Do, PhD, associate professor, Charles Bronfman Institute for Personalized Medicine at Mount Sinai, and Iain Forrest, MD-PhD candidate in Dr Do’s lab, discuss their hopes for their findings and how genetic data are being used in health care.
Mount Sinai Researchers Explain Implications of Genetic Testing for ProvidersMarch 12th 2022
Ron Do, PhD, associate professor, Charles Bronfman Institute for Personalized Medicine at Mount Sinai, and Iain Forrest, MD-PhD candidate in Dr Do’s lab, explain their study's implications for providers and how age plays a role in genetic variant penetrance.
Mount Sinai Researchers Explain Biobanks Used in Clinical Variants StudyMarch 4th 2022
Ron Do, PhD, associate professor, Charles Bronfman Institute for Personalized Medicine at the Icahn School of Medicine at Mount Sinai, and Iain Forrest, MD-PhD candidate in Dr Do’s lab, explain the differences between the biobanks used in their study on population-based penetrance of clinical variants.
Thermo Fisher Scientific Stages Open Call for Grant Proposals Supporting Oncology Molecular ProfilingMarch 2nd 2022
Thermo Fisher Scientific will begin accepting submissions for grant proposals focusing on molecular profiling in cancer spaces, where applicants could receive up to $200,000 in funding.
Mount Sinai Researchers Discuss Findings on Risk of Pathogenic, Loss-of-Function Clinical VariantsFebruary 26th 2022
Ron Do, PhD, associate professor, Charles Bronfman Institute for Personalized Medicine at the Icahn School of Medicine at Mount Sinai, and Iain Forrest, MD-PhD candidate in Dr Do’s lab, discuss the results of their recent study measuring population-based penetrance of pathogenic and loss-of-function clinical variants.
How Employers Can Achieve High-Value, Cost-Effective Oncology Care Through Genomic ProfilingFebruary 26th 2022
A webinar by the National Cancer Treatment Alliance discussed current use and diagnostic/therapeutic benefits of comprehensive genomic profiling in oncology, as well as recommendations for employers and benefit consultants considering biomarker testing.
Mount Sinai Researchers on Importance of Understanding Genetic Variants and Disease RiskFebruary 19th 2022
Ron Do, PhD, associate professor of the Charles Bronfman Institute for Personalized Medicine at the Icahn School of Medicine at Mount Sinai, and Iain Forrest, MD-PhD candidate in Dr Do’s lab, explain the importance of their recent study measuring population-based penetrance of pathogenic and loss-of-function clinical variants.
FDA Grants Breakthrough Device Designation to Foundation Medicine’s ctDNA TrackerFebruary 15th 2022
Foundation Medicine’s circulating tumor DNA (ctDNA) detection and monitoring assay, FoundationOne Tracker, was granted a Breakthrough Device Designation from the FDA, streamlining the approval and review processes to give patients and providers earlier access to the device.